Middleton, Massachusetts – November 6, 2025 – MavriX Bio, a clinical-stage biotechnology company focused on transformative genetic medicines, announced that the first patient has been dosed in the ASCEND-AS Phase 1/2 clinical trial of MVX-220, an investigational gene therapy for Angelman syndrome (AS). This marks the first clinical study of a gene therapy specifically designed for Angelman syndrome, a severe neurodevelopmental disorder with no approved disease-modifying treatments. The ASCEND-AS trial (NCT07181837) will evaluate safety, tolerability, and preliminary efficacy of MVX-220 in both adult and pediatric participants, encompassing a range of genetic subtypes, including deletion, uniparental disomy, and imprinting center defects. The program is backed by the Foundation for Angelman Syndrome Therapeutics (FAST) and AS2Bio, an accelerator advancing early-stage genetic therapies.
Science Significance
MVX-220 is designed to restore functional expression of the UBE3A gene in neurons, which is lost in individuals with Angelman syndrome. The therapy employs a targeted adeno-associated virus (AAV) delivery system to the central nervous system to replace or reactivate the missing gene. By addressing the root genetic cause of AS, MVX-220 represents a potential one-time treatment aimed at modifying the disease course, rather than only alleviating symptoms. According to Dr. Elizabeth Berry-Kravis, Principal Investigator at Rush University Medical Center, “This trial represents a new era in Angelman syndrome research, directly targeting the genetic origin of the disorder through neuron-level UBE3A restoration.” Preclinical studies demonstrated that MVX-220 effectively increased UBE3A expression in neuronal models, normalizing several neurobehavioral markers associated with AS. These promising findings laid the foundation for first-in-human evaluation under the ASCEND-AS protocol.
Regulatory Significance
In conjunction with this clinical milestone, the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MVX-220 for the treatment of Angelman syndrome. This designation acknowledges the therapy’s potential to address a rare condition affecting fewer than 200,000 individuals in the United States. The Orphan status provides critical regulatory incentives, including seven years of market exclusivity, tax credits for clinical testing, and potential waiver of FDA user fees. The designation highlights the agency’s support for innovative genetic therapies in underserved populations. “Dosing our first participant is a pivotal step toward realizing the potential of gene-targeted therapies for Angelman syndrome,” said Jennifer Panagoulias, Chief Operating Officer of MavriX Bio. “It reflects the collaborative dedication of the Angelman community, our research partners, and the commitment to developing first-in-class treatments.” The ASCEND-AS study is being conducted in the U.S. under an Investigational New Drug (IND) application, with plans for future global expansion pending early safety data.
Business Significance
Advertisement
For MavriX Bio, this milestone strengthens its position in the gene therapy and rare disease sector, advancing a first-in-class asset that originated at the University of Pennsylvania with full funding support from FAST. The program was later licensed to MavriX Bio through AS2Bio’s development accelerator, enabling efficient transition from preclinical discovery to clinical execution. This integrated partnership model — combining academic innovation, patient advocacy funding, and biotech commercialization — offers a sustainable pathway for accelerating genetic therapy pipelines. MavriX Bio’s collaboration with GEMMABio and other research partners also highlights a growing trend of consortium-based approaches in translational medicine. As a portfolio company of AS2Bio, MavriX benefits from shared scientific expertise, infrastructure, and regulatory strategy, reducing early development costs while expediting clinical initiation. If MVX-220 demonstrates durable efficacy, it could establish MavriX Bio as a pioneer in precision neurogenetics and potentially attract larger-scale partnerships or investment opportunities in 2026.
Patients’ Significance
For individuals and families affected by Angelman syndrome, the initiation of ASCEND-AS represents a turning point of hope and progress. Angelman syndrome affects approximately 1 in 12,000–20,000 people worldwide, leading to severe developmental delays, motor impairments, seizures, sleep disorders, and speech difficulties. There are currently no approved disease-modifying therapies — existing treatments only manage symptoms. MVX-220 aims to replace the lost UBE3A gene function in neurons, potentially reversing or stabilizing disease progression after a single administration. “This trial is more than a scientific milestone — it’s a moment of possibility for families who have waited decades for a therapy that targets the root cause, not the symptoms, of Angelman syndrome,” said Panagoulias.
Policy Significance
The ASCEND-AS program demonstrates the growing effectiveness of patient-driven, public–private collaborations in rare disease innovation. Organizations such as FAST and AS2Bio have pioneered a shared-development model where patient advocacy groups fund and guide early-stage programs, bridging the traditional “valley of death” between discovery and clinical trials. Regulators and policymakers increasingly recognize the role of such models in accelerating equitable access to transformative therapies. Successful progress of MVX-220 could inform future FDA and EMA frameworks for evaluating gene therapies in pediatric neurodevelopmental conditions, particularly where standard endpoints are not well-defined. The ASCEND-AS trial also reflects broader policy priorities supporting orphan drug innovation, gene therapy regulation, and rare disease clinical infrastructure — all critical elements for advancing the next generation of genomic medicine.
Transaction Highlights
The first patient has been dosed in the ASCEND-AS Phase 1/2 study, marking the first-ever gene therapy trial for Angelman syndrome. The therapy, MVX-220, developed at the University of Pennsylvania and advanced through AS2Bio with funding from FAST, has also received FDA Orphan Drug Designation. The trial will assess safety, tolerability, and early efficacy across adult and pediatric cohorts, laying the groundwork for future pivotal studies and global regulatory submissions.
Source: AS2Bio Press Release
